Filing Flows › Aquestive Therapeutics (AQST) › Manufacture and supply revenue revenue
Aquestive Therapeutics (AQST) Manufacture and supply revenue revenue by quarter
Aquestive Therapeutics' Manufacture and supply revenue revenue was $6.7M in Q3 2026 (third quarter 2026), -44% from Q2 2026. Over the last 6 quarters it ranged from $6.7M (Q3 2026) to $12.0M (Q4 2025).
| Quarter | Manufacture and supply revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.7M | -44% | -42% |
| Q2 2026 | $11.9M | +35% | — |
| Q1 2026 | $8.8M | -27% | +22% |
| Q4 2025 | $12.0M | +4% | — |
| Q3 2025 | $11.5M | +59% | — |
| Q1 2025 | $7.2M | — | — |
Q3 2026 at a glance
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Aquestive Therapeutics' Manufacture and supply revenue revenue?
Aquestive Therapeutics' Manufacture and supply revenue revenue was $6.7M in Q3 2026 (third quarter 2026), -44% from Q2 2026.
How has Aquestive Therapeutics' Manufacture and supply revenue revenue changed?
Over the last 6 quarters it ranged from $6.7M (Q3 2026) to $12.0M (Q4 2025).
Q3 2026 results → · How Aquestive Therapeutics makes money →